Molecular predictive factors of outcome of radiotherapy in cervical cancer

Neoplasma

Volumn 58, Issue 6, 2011, Pages 469-475

  Petera, J ^a   Sirak, I ^a   Beranek, M ^a   Vosmik, M ^a   Drastikova, M ^a   Paulikova, S ^a   Soumarova, R ^b  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b Cancer Centre Novy Jicin   (Czech Republic)

Author keywords

Bcl 2; Cervical cancer; COX 2; EGFR; HER 2; HPV; Ki 67; Molecular predictive factors; Radiotherapy; Survivin

Indexed keywords

ATM PROTEIN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; MEMBRANE RECEPTOR; NITRIC OXIDE SYNTHASE; PROTEIN BCL 2; PROTEIN KINASE B BETA; PROTEIN P21; PROTEIN P53; SURVIVIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; TUMOR MARKER;

ANGIOGENESIS; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL PROLIFERATION; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; HYPOXIA; MICROARRAY ANALYSIS; MOLECULAR DIAGNOSIS; PREDICTIVE VALUE; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UTERINE CERVIX CANCER; WART VIRUS; FEMALE; HUMAN; METABOLISM; UTERINE CERVIX TUMOR;

FEMALE; HUMANS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84856392090     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2011_06_469     Document Type: Review

References (64)

1. Perez CA, Brady LW, editors. Principles and practice of radiation oncology. Philadelphia: Lippincott Williams and Wilkins, 2008.
2. Oka k, Suzuki Y, Nakano T. Expression of p27 and p53 in cervical squamous cell carcinoma patients treated with radiotherapy alone: Radiotherapeutic effect and prognosis. Cancer 2000; 88: 2766-2773. doi:10.1002/1097-0142(20000615)88:12<2766::AID-CNCR15>3.0.CO;2-G.
3. Tsuda H, Jiko K, Tsugane S, Yajima M, Yamada T, et al. Prognostic value of p53 protein accumulation in cancer cell nuclei in adenocarcinoma of the uterine cervix. Jpn J Cancer Res 1995; 86: 1049-1053.
4. Lu X, Toki T, Konishi I, Nikaido T, Fujii S. Ex-pression of p21WAF1/CIP1 in adenocarcinoma of the uterine cervix: a possible immunohistochemical marker of a favorable prognosis. Cancer 1998; 82: 2409-2417. doi:10.1002/(SICI)1097-0142(19980615)82:12<2409::AIDCNCR15>3.0.CO;2-T.
5. Yamashita H, Murakami N, Asari T, Okuma K, Ohtomo K, et al. Correlation among six biologic factors (p53, p21(WAF1), MIB-1, EGFR, HER2, and Bcl-2) and clinical outcomes after curative chemoradiation therapy in squamous cell cervical cancer. Int J Radiation Oncol Biol Phys 2009; 74: 1165-1172.
6. Niibe Y, Nakano T, Ohno T, Tsujii H, Oka K. Relation-ship between p21/WAF-1/CIP-1 and apoptosis in cervical cancer during radiation therapy. Int J Radiat Oncol Biol Phys 1999; 44: 297-303. doi:10.1016/S0360-3016(99)00026-7.
7. Beskow C, Kanter L, Holgersson A, Nilsson B, Frankendal B, et al. Expression of DNA damage response proteins and complete remission after radiotherapy of stage IB-IIA of cervical cancer. Br J Cancer 2006; 94: 1683-1689.
8. Nakano T, Oka K. Differential values of Ki-67 index nad mitotic index of proliferating cell population: An assessment of cell cycle and prognosis in radiation therapy for cervical cancer. Cancer 1993; 72: 2401-2408. doi:10.1002/1097-0142(19931015)72:8<2401:AID-CNCR2820720818>3.0.CO;2-D.
9. Cole DJ, Brown DC, Crossley E, Alcock CJ, Gatter KC. Carcinoma of the cervix uteri: an assessment of the relationship of tumour proliferation to prognosis. Br J Cancer 1992; 65: 783-785. doi:10.1038/bjc.1992.167.
10. Levine EL, Renehan A, Gossiel R, Davidson SE, Roberts SA, et al. Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma. Radiother Oncol 1995; 37: 1-9. doi:10.1016/0167-8140(95)01622-N.
11. Oka K, Arai T. MIB1 growth fraction is not related to prognosis in cervical squamous cell carcinoma treated with radiotherapy. Int J Gynecol Pathol 1996; 15: 23-27. doi:10.1097/00004347-199601000-00004.
12. Lee CM, Shrieve DC, Zempolich KA, Lee RJ, HAM-MOND E, et al. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt(P-Akt) and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol 2005; 99: 415-421. doi:10.1016/j.ygyno.2005.05.045.
13. Fuchs I, Vorsteher N, Bühler H, Evers K, Sehouli J, et al. The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma. Anticancer Res 2007; 27: 959-963.
14. Gaffney DK, Haslam D, Tsodikov A, Hammond E, Seeman J, et al. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys, 2003; 56: 922-928. doi:10.1016/S0360-3016(03)00209-8.
15. Nakano T, Oka K, Ishikawa A, Morite S. Correlation of cervical carcinoma c-erb B-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma. Cancer 1997; 79: 513-520. doi:10.1002/(SICI)1097-0142(19970201)79:3<513:AID-CNCR13>3.0.CO;2-6.
16. Kihana T, Tsuda H, Teshima S, Nomoto K, TSugane S, et al. Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Cancer 1994; 73: 148-153. doi:10.1002/1097-0142(19940101)73:1<148:AID-CNCR2820730125>3.0.CO;2-C.
17. Leung TW, Cheung AN, Cheng DK, Wong LC, Ngan HY. Expressions of c-erbB-2, epidermal growth factor receptor and pan-ras protooncogenes in adenocarcinoma of the cervix: correlation with clinical prognosis. Oncol Rep 2001; 8: 1159-1164.
18. Ngan HY, Cheung AN, Liu SS, Cheng DK, Ng TY, Wong LC. Abnormal expression of epidermal growth factor receptor and c-erbB2 in squamous cell carcinoma of the cervix: correlation with human papillomavirus and prognosis. Tumour Biol 2001; 22: 176-183. doi:10.1159/000050613.
19. Wootipoom V, Lekhyananda N, Phungrassami T, Boonyaphiphat P, THONGSUKSAI P. Prognostic significance of Bax, Bcl-2 and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy. Gynceol Oncol 2004; 94: 636-642. doi:10.1016/j.ygyno.2004.03.012.
20. Pillai MR, Jayaprakash PG, Nair MK. Bcl-2 immunoreactivity but not p53 accumulation associated with tumour response to radiotherapy in cervical carcinoma. J Cancer Res Clin Oncol 1999; 125: 55-60. doi:10.1007/s004320050242.
21. Rajkumar T, Rajan S, Baruah RK, Majhi U, SEL-VALUXUMI G, et al. Prognostic significance of Bcl-2 and p53 protein expression in stage IIB and IIIB squamous cell carcinoma of the cervix. Eur J Gynaecol Oncol 1998; 19: 556-60.
22. Chung TK, Cheung TH, Lo WK, Yim SF, Krajewski S, et al. Expression of apoptotic regulators and their sigificance in cervical cancer. Cancer Lett 2002; 180: 63-68. doi:10.1016/ S0304-3835(01)00842-4.
23. Jain D, Srinivasan R, Patel FD, Kumari Gupta S. Evaluation of p53 and Bcl-2 expression as prognostic markers in invasive cervical carcinoma stage IIb/III patients treated by radiotherapy. Gynecol Oncol 2003; 88: 22-28. doi:10.1006/gyno.2002.6838.
24. Harima Y, Harima K, Shikata N, Oka A, Ohnishi T, et al. Bax and Bcl-2 expressions predict response to radiotherapy in human cervical cancer. J Cancer Res Clin Oncol 1998; 124: 503-510. doi:10.1007/s004320050206.
25. Beskow C, Kanter L, Holgersson A, Nilsson B, Frankendal B, et al. Expression of DNA damage response proteins and complete remission after radiotherapy of stage IB - IIA cervical cancer. Br J Cancer 2006; 94: 1683-1689.
26. Beskow C, Skikunoene J, Holgersson A, Nilsson B, Leensohn R, et al. Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku 70 and Ku86. Br J Cancer 2009; 101: 816-821. doi:10.1038/ sj.bjc.6605201.
27. Harima Y, Sawada S, Nagata K, Sougawa M, Ohnishi T. Human papilloma virus (HPV) DNA associated with prognosis of cervical cancer after radiotherapy. In J Radiat Oncol Biol Phys 2002; 52: 1345-1351.
28. Kim JY, Park S, Nam BH, Roh JW, Lee CH, et al. Low initial human papilloma viral load implicates worse prognosis in patients with uterine cervical cancer treated with radiotherapy. J Clin Oncol, 2009; 27: 5088-5093. doi:10.1200/JCO.2009.22.4659.
29. WANG CC, LAI CH, HUANG HJ, CHAO A, CHANG CJ, et al. Clinical effect of human papillomavirus genotypes in patients with cervical cancer unergoing primary radiotherapy. Int J Radiat Oncol Biol Phys 2010; 78: 1111-1120. doi:10.1016/j.ijrobp.2009.09.021.
30. KIM TJ, LEE JW, SONG SY, CHOI JJ, CHOI CH, et al. Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br J Cancer 2006; 94, 1678-1682.
31. KIM YB, KIM GE, CHO NH, PYO HR, SHIM SJ, et al. Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy. Cancer 2002, 95: 531-539. doi:10.1002/ cncr.10684.
32. Ishikawa H, Ohno T, Kato S, Wakatsuki M,Iwakawa M, et al. Cyclooxygenase-2 impairs treatment effects of radiotherapy for cervical cancer by inhibition of radiation-induced apoptosis. Int J Radiat Oncol Biol Phys 2006; 66: 1347-1355. doi:10.1016/j.ijrobp.2006.07.007.
33. KIM HJ, WU HG, PARK IA, HA SW. High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003; 55: 16-20. doi:10.1016/S0360-3016(02)03821-X.
34. CHEN HH, SU WC, CHOU CY, GUO HR, HO SY, et al. Increased expression of nitric oxide synthase and cyclooxygenase-2 is associated with poor survival in cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2005; 63: 1093-1100. doi:10.1016/j.ijrobp.2005.03.062.
35. BACHTIARY B, SCHINDL M, PÖTTER R, DREIER B, KNOCKE TH, et al. Overexpression of hypoxia-inducible factor 1α indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 2003; 9: 2234-2240.
36. BURRI P, DJONOV V, AEBERSOLD DM, LINDEL K, STUDER U, et al. Significant correlation of hypoxia-inducible factor-1alpha with treatment outocme in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2003; 56: 494-501. doi:10.1016/S0360-3016(02)04579-0.
37. ISHIKAWA H, SAKURAI H, HASEGAWA M, MITSUHASHI N, TAKAHASHI M, et al. Expression of hypoxic-inducible factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2004; 60: 513-521. doi:10.1016/ j.ijrobp.2004.03.025.
38. KAWANAKA T, KUBO A, IKUSHIMA H, SANO T, TAKEGAWA Y, et al. Prognostic significance of HIF-2alpha expression on tumor infiltrating macrophages in patients with uterine cervical cancer undergoing radiotherapy. J Med Invest 2008; 55: 78-86. doi:10.2152/jmi.55.78.
39. ZUSTERZEEL PL, SPAN PN, DIJKSTERHIUS MG, THOMAS CM, SWEEP FC, et al. Serum vascular endothelial growth factor: a prognostic factor in cervical cancer. J Cancer Res Clin Oncol 2009; 135: 283-290. doi:10.1007/s00432-008-0442-y.
40. KANG JO, HONG SE. The prognostic effect of VEGF expression in squamous cell carcinoma of the cervix treated with radiation therapy alone. J Korean Med Sci 2004;19: 693-697. doi:10.3346/jkms.2004.19.5.693.
41. BACHTIARY B, SELZER E, KNOCKE TH, PÖTTER R, OBERMAIR A. Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survival. Cancer Lett 2002; 179: 197-203. doi:10.1016/S0304-3835(01)00872-2.
42. GARG AK, JHINGRAN A, KLOPP AH, AGGARWAL BB, KUNNUMAKKARA AB, et al. Expression of nuclear transcription factor kappa B in locally advanced human cervical cancer treated with definitive chemoradiation. Int J Radiat Oncol Biol Phys 2010; 78: 1331-1336. doi:10.1016/ j.ijrobp.2009.09.044.
43. HARIMA Y, SAWADA S, MIYAZAKI Y, KIN K, ISHIKARA H, et al. Expression of Ku80 in cervical cancer correlates with response to radiotherapy and survival. Am J Clin Oncol 2003; 26: 80-85. doi:10.1097/01.COC.0000077938.48974.59.
44. WILSON CR, DAVIDSON SE, MARGISON GP, JACKSON SP, HENDRY JH, et al. Expression of Ku70 correlates with survival in carcinoma of the cervix. Br J Cancer 2000; 83: 1702-1706. doi:10.1054/bjoc.2000.1510.
45. JU XZ, YANG JM, ZHOU XY, LI ZT, WU XH. EMMPRIN expression as a prognostic factor in radiotherapy of cervical cancer. Clin Cancer Res 2008; 14: 494-501. doi:10.1158/1078-0432.CCR-07-1072.
46. SUZUKI Y, OKA K, YOSHIDA D, SHIRAI K, OHNO T, et al. Correlation between survivin expression and locoregional control in cervical squamous cell carcinomas treated with radiation therapy. Gynecol Oncol 2007; 104: 642-646. doi:10.1016/j.ygyno.2006.10.005.
47. KLOPP AH, JHINGRAN A, RAMDAS L, STORY MD, BROADUS RR, et al. Gene expression changes in cervical squamous cell carcinoma after initiation of chemoradiation and correlation with clinical outcome. Int J Radiat Oncol Biol Phys 2008; 71: 226-236. doi:10.1016/j.ijrobp.2007.10.068.
48. KITAHARA O, KATAGIRI T, TSUNODA T, HARIMA Y, NAKAMURA Y. Classification of sensitivity or resistance of cervical cancers to ionizing radiation according to expression profiles of 62 genes selected by cDNA microarray analysis. Neoplasia 2002; 4: 295-303. doi:10.1038/sj.neo.7900251.
49. QING Y, YANG XQ, ZHONG ZY, LEI X, XIE JY, et al. Microarray analysis of DNA damage repair gene expression profiles in cervical cancer cells radioresistant to 252Cf neutron and X-rays. BMC Cancer 2010; 10: 71-87. doi:10.1186/1471-2407-10-71.
50. RAJKUMAR T, VIJAYALAKSHMI N, SABITHA K, SHIRLEY S, SELVALUXMY G, et al. A 7 gene expression score predicts for radiation response in cancer cervix. BMC Cancer 2009; 9: 365. doi:10.1186/1471-2407-9-365.
51. WONG YF, SELVANAYAGAM ZE, WEI N, PORTER J, VITTAL R, et al.: Expression genomics of cervical cancer: Molecular classification and prediction of radiotherapy response by DNA microarry. Clin Cancer Res 2003; 9: 5486-5492.
52. Tewari D, Monk BJ, Alghazi MS, Parker R, Heck JD, et al. Gene expression profiling of in vitro radiation resistance in cervical carcinoma: a feasibility study. Gynecol Oncol 2005; 99: 84-91. doi:10.1016/j.ygyno.2005.05.043.
53. Andreassen CN, Overgaard J, Alsner J, Overgaard M, Herskind C, et al. ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys 2006; 64: 776-783. doi:10.1016/j.ijrobp.2005.09.014.
54. HO AY, FAN G, ATENCIO DP, GREEN S, FORMENTI SC, et al. Possession of ATM sequence variants as predictor for late normal tissue responses in breast cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2007, 69: 677-684. doi:10.1016/j.ijrobp.2007.04.012.
55. HALL EJ, SCHIFF PB, HANKS GE, BRENNER DJ, RUSSO J, et al. A preliminary report: frequency of A-T heterozygotes among prostate cancer patients with severe late responses to radiation therapy. Cancer J Sci Am 1998; 4: 385-389.
56. CESARETTI JA, STOCK RG, LEHRER S, ATENCIO DA, BERNSTEIN JL, et al. ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Int J Radiat Oncol Biol Phys 2005; 61: 196-202. doi:10.1016/j.ijrobp.2004.09.031.
57. ANDREASSEN CN, ALSNER J. Genetic variants and normal tissue toxicity after radiotherapy: a systematic review. Radiat Oncol 2009; 92: 299-309. doi:10.1016/j.radonc.2009.06.015.
58. De Ruyck K, Van Eijkeren M, CLAES K, MORTHIER R, DE PAEPE A, et al. Radiation - induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: association with single nukleotide polymorphism in XRCC1, XRCC3 and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes. Int J Radiat Oncol Biol Phys 2005; 62: 1140-1149. doi:10.1016/ j.ijrobp.2004.12.027.
59. De Ruyck K, Van Ejkeren M, CLAES K, BACHER K, VRAI A, et al. TGFbeta1 polymorphisms and late clinical radiosensitivity in patiens treated for gynecologic tumors. Int J Radiat Oncol Biol Phys 2006; 65: 1240-1248. doi:10.1016/ j.ijrobp.2006.03.047.
60. ISHIKAWA A, SUGA T, SHOJI Y, KATO S, OHNO T, et al. Genetic variants of NPAT-ATM and AURKA are associated with an early adverese reactions in the gastointestinal tract of patients with cervical cancer treated with pelvic radiation therapy. Int J Radiat Oncol Biol Phys 2010; article in press.
61. NIU N, QIN Y, FRIDLEY BL, HOU J, KALARI KR, et al. Radiation pharmacogenomics: A genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Research; 20: 1482-1492. doi:10.1101/gr.107672.110.
62. KERNS SL, OSTRER H, STOCK R, LI W, Moore J, et al. Genome wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African -American men after radiotherapy for prostate cancer-Int J Radiat Oncol Biol Phys 2010; 78: 1292-1300. doi:10.1016/j.ijrobp.2010.07.036.
63. SMITH L, QUTOB P, WATSON MG, BEAVIS AW, POTTS D, et al. Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for 26S proteasome? Neoplasia 2009; 11: 1194-1207.
64. CAI XW, SHEDDEN K, AO X, DAVIS M, FU XL et al. Plasma proteomic analysis may identify new markers for radiation induced lung toxicity in patients with non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2010; 77: 867-876. doi:10.1016/j.ijrobp.2010.01.038.